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Site-selective chemical bioconjugation reactions are enabling tools
for the chemical biologist. Guided by a careful study of the seleno-
methionine (SeM) benzylation, we have refined the reaction to
meet the requirements of practical protein bioconjugation. SeM is
readily introduced through auxotrophic expression and exhibits
unique nucleophilic properties that allow it to be selectively modi-
fied even in the presence of cysteine. The resulting benzylseleno-
nium adduct is stable at physiological pH, is selectively labile to
glutathione, and embodies a broadly tunable cleavage profile. Spe-
cifically, a 4-bromomethylphenylacetyl (BrMePAA) linker has been ap-
plied for efficient conjugation of complex organic molecules to SeM-
containing proteins. This expansion of the bioconjugation toolkit has
broad potential in the development of chemically enhanced proteins.
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Protein bioconjugation has been used to create constructs vitalfor elucidating pathways underlying human disease as well as
several important classes of established therapeutics, including
constrained peptides, antibody–drug conjugates (ADCs), and
polyethylene glycol-modified proteins (1–7). The most useful
protein modification strategies are chemoselective, are site spe-
cific, and have fast reaction kinetics (since biomolecules are usu-
ally modified at submillimolar concentrations) (8). While proteins
can be assembled synthetically or semisynthetically, the ability to
modify biologically expressed proteins allows for efficient bio-
production of modified domains. Most bioconjugation strategies
target the nucleophiles of naturally occurring amino acids, such as
the primary amines present at the protein N terminus or on lysine
residues (9, 10) and the cysteine thiol (1, 2). Less common strat-
egies target tyrosine (11, 12), arginine (13), and methionine (14),
but these procedures are usually sluggish or dependent on com-
plex reagents (10, 15). More recently, a redox-based linker has
been developed for methionine-based sulfilimide bioconjugation
(16–20), as well as a photo-redox–enabled method (21), demon-
strating the potential utility of this residue.
Enhanced site selectivity and chemo-selectivity can be obtained
through biological expression with unnatural amino acids (UAAs)
(22–25). Amber suppression and genetic code expansion allow for
the incorporation of unique and orthogonal groups, such as ke-
tones and azides, for use in oxime ligations and Cu(I)-catalyzed
azide-alkyne cycloaddition, respectively. Although amber expres-
sion is frequently utilized with success in the laboratory, the syn-
thesis of unnatural amino acids and scale up can be limiting.
Alternatively, certain UAAs, like selenomethionine, can be intro-
duced through auxotrophic expression. Auxotrophic expression of
selenomethionine (SeM) is an efficient and robust technique that
has been utilized for the production of heavy labeled proteins by
crystallographers for decades (26–28). Another popular technique
utilizes Met auxotrophic systems to introduce azidohomoalanine or
homopropargylglycine into expressed proteins. These selectively
reactive click handles have been employed successfully in bacterial
and mammalian cells for recombinant protein or direct cell surface
labeling (22, 29–31).
The selenomethionine selenoether displays interesting chem-
ical properties, as selenoethers are uniquely nucleophilic and
sensitive to mild redox transformations (32). Methionine (which
is replaced by selenomethionine in auxotrophic systems) is the
second rarest amino acid in vertebrates which allows surface-
exposed residues to be engineered for selective chemical modi-
fication while native buried residues can be left unaltered as not
to perturb protein structure (16). The unique chemical proper-
ties and the facile introduction into expressed proteins make
selenomethionine a prime target for the development of addi-
tional protein chemistries. Also, SeM can be alkylated with
benzyl bromides under conditions which do not modify Met;
typically Met alkylation reactions require extended reaction
times and high concentrations of alkylating reagents (high mil-
limolar to saturating) (14, 33–35).
Selenomethionine has been shown to be selectively modified with
benzyl bromides under acidic aqueous conditions, but the reaction
has yet to be embraced as a protein bioconjugation strategy (34–36).
Here, a detailed study of the selenomethionine benzylation reaction
has been performed, leading to the identification of labeling re-
agents that form the basis of a highly chemoselective and tunable
bioconjugation strategy (Fig. 1). The robust ligation kinetics of the
newly identified 4-bromomethylphenylacetyl (BrMePAA) linker
suggest the SeM benzylation reaction will be widely applicable as a
protein-labeling strategy.
Significance
The manipulation of proteins in a site-selective manner underpins
much of modern protein chemistry. A careful evaluation of seleno-
methionine benzylation led to the identification of a highly efficient
bromobenzyl linker for protein bioconjugation. This selenonium-
forming ligation reaction can efficiently link proteins to other com-
plex molecules such as synthetic peptides, polymers, or reactive
handles. The selenonium product is sufficiently stable at physiolog-
ical pH, yet is efficiently cleaved by glutathione at intracellular con-
centrations. Selenomethionine benzylation is a broadly applicable
tool for engineering of complex macromolecules.
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pH Independence of the Selenomethionine Benzylation. The pH de-
pendence of SeM benzylation was explored. Peptide 1 (2.5 mM)
(Fig. 2A) in a solution of 30% MeCN, 5% dimethylsulfoxide
(DMSO), and 10 mM ascorbic acid was exposed to 2 equiv. BnBr
in an aqueous solution, buffered at pH 2 to 7.4 (Fig. 2B). Con-
sistent reaction profiles were observed for conversion of 1 to the
corresponding benzylated species 2 which suggests that the SeM
benzylation is pH independent, over the range of pH 2 to 7.4
(Fig. 2B). This observation is notable as all other proteogenic nu-
cleophiles are protonatable and thus rendered less reactive as pH
decreases.
Selenomethionine Orthogonality. Upon treating peptide 1 with
maleimidopropioic acid, under standard Cys labeling conditions
(1), no SeM conjugation is observed at pH 6 while only minor
reactivity is observed at pH 7.5 (SI Appendix). This is consistent
with our previous observation of the lack of reactivity of iodoa-
cetamide at pH 2 (34) and may allow for SeM benzylation to be
used in concert with or augment other bioconjugation techniques.
Selenomethionine Benzylation Kinetics. To evaluate the order of the
reaction, initial rates were measured over a range of reactant con-
centrations for benzyl bromides with electron-donating (p-CH2-
COO−) and electron-withdrawing (p-CN) substituents. Benzylation
of 1 with bromomethylphenylacetic acid and p-cyanobenzylbromide
shows a first-order rate dependence in both reactants (SI Appendix).
The observed rate order implies that the reaction mechanism does
not change across the electronic perturbations tested.
Hammett Study of Selenomethionine Benzylation. Benzyl bromides
with electron-donating and -withdrawing substituents were evalu-
ated in the selenomethionine benzylation reaction. Benzyl bromides
with various parasubstituents were used in the benzylation of 1, and
log (kp-X/kp-H) was plotted against Hammett constants from the
literature (37). The study shows a clear inverse Hammett correla-
tion, with a ρ of −1.4 (Fig. 3B) (37, 38). Initial rate measurements
revealed that the reaction is first order with respect to [peptide] and
[BnBr]. The kinetic data were fitted to a second-order integrated
rate equation to obtain rate constants of 0.07 M−1·s−1 for the
benzamide linker, 0.02 M−1·s−1 for the quaternary ammonium
linker, and 0.7 M−1·s−1 for the BrMePAA linker (Fig. 3C). This
phenomenon was unexpected, as most bimolecular substitution re-
actions, which are first order in both reactants, would be expected to
show a positive Hammett correlation.
Benzylselenonium Conjugate Stability. The stability of the benzyl-
selenonium adducts under physiological conditions was profiled.
Stability in phosphate-buffered saline (PBS), pH 7.4, mimicking
human blood plasma was explored with two distinct benzylsele-
nonium derivatives of 1. These constructs exhibited stability with
half-lives of 43 and 24 d for the benzyl bromide and 4-Me ben-
zylbromide adduct, respectively (Fig. 4A). To probe cytosolic
stability, three benzylselenonium adducts of 1 were incubated in
7.5 mM glutathione (GSH) in PBS, pH 7.4 (39, 40). The conjugate
with an electron-withdrawing group (4NO2) degraded rapidly; less
than 5% of the 4-nitrobenzyl bromide adduct remained after 2 h,
while the electron-donating (−CH2COO−) analog remained 50%
intact at the same time point (Fig. 4B). This stability profile could
allow benzylated SeM species to be used in various biomolecular
probe and therapeutic applications.
Selenomethionine Benzylation in Bioconjugation. The benzylation of
selenomethionine displays multiple unique attributes that should
allow it to be employed as a useful bioconjugation strategy. In
contrast to most proteogenic nucleophiles, which become less reac-
tive at low pH (as protonation occurs), the nucleophilicity of SeM is
unaffected by pH. Similarly, the electronic dependence of the benzyl
bromide linker on rate is the inverse of other proteogenic nucleo-
philes. Although SeM reacts fastest with electron-donating benzyl
bromides, the proteogenic nucleophiles should react faster with
benzyl bromides bearing electron-withdrawing substituents, as those
result in a more electrophilic benzylic carbon. Therefore, the elec-
tronic demands and pH dependence of the SeM nucleophile are the
opposite to those of most other nucleophiles present in biological
macromolecules, which results in high chemoselectivity toward SeM.
Importantly, SeM is orthogonal to commonly employed cysteine-
labeling reagents such as maleimide and iodoacetamide.
It is noteworthy that the stability of the sulfonium linker can
be modulated. The selenomethionine–sulfonium adducts display
half-lives in biological environments that would allow them to be
utilized for the creation of serum stable protein conjugates such
as ADCs or constructs designed for controlled release (3, 5).
Fig. 1. The selenomethionine benzylation.
Fig. 2. (A) The selenomethionine benzylation reaction conditions. (B) pH
dependence of SeM benzylation (2.5 mM peptide 1, 5 mM BnBr, 30% MeCN,
5% DMSO, 1 mM Boc-Tyr-OH as internal standard). Some error bars are
smaller than point markers.
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Also, since these benzyl selenonium linkers exhibit the opposite
degradation kinetics in serum versus in cytosol, an interesting
opportunity is presented. One can envision creating a tunable
linker which exhibits a long, stable half-life while in circulation but
upon cell internalization is readily cleaved by intracellular GSH to
release a payload. The benzyl selenonium linkage is highly tun-
able, allowing one to use electronic perturbation to modulate
conjugation and cleavage rates. Taken together these qualities
should allow the benzylation of SeM to be readily applied to
protein bioconjugation.
SeM Benzylation as a Strategy for Protein Bioconjugation. Insights
gained from the Hammett study (Fig. 3B) led to the selection of
BrMePAA as a general bioconjugation linker. BrMePAA is readily
available, shelf stable, and easily incorporated into tags of interest
by either solution or solid-phase methods. To test the utility of this
linker, the albumin-binding, three-helix bundle SpA domain, 3, was
selected due to its utility as a half-life–extending moiety in vivo
(Fig. 5A) (4, 41). The naturally occurring solvent-exposed Met9 was
replaced with a SeM and Cys22 was added to evaluate chemo-
selectivity in the presence of a free thiol. In the first protein-labeling
experiment, protein 3 was exposed to tag 4 at pH 6 for 6 h. This
reaction resulted in 75% of the desired (SeM-conjugated) product
and 25% of a side product in which both the SeM and the Cys were
labeled (Fig. 5A). In a subsequent reaction, the pH was adjusted to 5
while leaving all other parameters constant. After 6 h, the mono-
selenonium product (82%) was observed along with 15% starting
material, and only a trace of the doubly labeled material was observed
(Fig. 5A). Using these selective conditions, two additional tags, a
3xFlag tag 5 and a chromophore-containing tag 6, were used to label
protein 3 (Fig. 5B). These tags label only the SeM residue, resulting in
complete conversion to the tagged conjugate with no detectable
double-labeled side product or starting material (Fig. 5B).
The protein GATE-16, an autophagic ubiquitin-like protein, was
auxotrophically expressed with selenomethionine as a Tev fusion 7
(Fig. 6A). This construct contains four selenomethionines: two sol-
vent exposed, one buried but in a flexible N-terminal region, and one
fully buried in the core of the protein. GATE-16 also contains a
solvent-exposed cystine. Treating 7 (200 μM) with tag 8 (800 μM, 4
equiv. relative to protein) at pH 5 for 12 h yielded a dual-labeled
species with minor single and triple addition products (Fig. 6C). SeM
over Cys selectivity was confirmed through subsequent treatment
with N-ethylmaleimide (800 μM), which led to complete labeling of
the solvent-exposed cysteine (SI Appendix). Regioselective labeling
at SeM positions 3, 6, and 63 was confirmed by both trypsin and
chymotrypsin digest and high-performance liquid chromatography–
mass spectrometry (HPLC-MS) (SI Appendix). Importantly the
buried SeM93 and exposed Cys17 showed no evidence of labeling
with 8 (SI Appendix). Chemoselectivity for SeM over the other
proteogenic nucleophiles, even thiols, suggests a broad utility in
bioconjugation.
Fig. 3. (A) The selenomethionine benzylation reaction conditions. (B)
Hammett correlation of the selenomethionine benzylation [the Hammett
constant for p-CH2NEt3
+ was estimated from p-CH2N(Me)3
+]. (C) Conversion
of 1 to the corresponding selenonium species of representative linkers.
Shown are BrMePAA (Green), benzamide (blue), and quaternary ammonium
linker (red) [1 mM 1, 2 mM R-BnBr, 1 mM Boc-Tyr-OH (internal standard),
10 mM ascorbic acid, 40 mM MES pH 6, 30% MeCN, 5% DMSO in water].
Rate constants were derived by fitting rate conversion experiments to a
second-order integrated rate law.
Fig. 4. (A) Benzyl-selenonium stability in plasma mimic (1 mM peptide, in
PBS pH 7.4, monitored by HPLC). (B) Benzyl selenonium stability in cytosol
mimic (1 mM peptide, in PBS pH 7.4, with 7.5 mM GSH, monitored by HPLC).
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SeM maltose-binding protein (His-MBP-Tev) was also evalu-
ated for selenomethionine bioconjugation. The MBP construct 9
contained seven SeM residues, one of which is fully solvent ex-
posed (located in the unstructured C-terminal region, SeM389),
two of which are partially solvent exposed (SeM 164 and 337),
and four which are completely buried (SeM 220, 240, 346, and
356) (Fig. 7A). Treating MBP 9 (50 μM) with tag 8, at pH 5 for
12 h, yielded a singly labeled major product with additional dual-
and triple-labeled conjugate species observed (Fig. 7C). The
conjugation sites were confirmed by trypsin digest to be SEM
164, 337, and 389 (SI Appendix). These conditions resulted in a
primary conjugation product that was singly labeled at the most
solvent-exposed residue, SeM389. These experiments suggest sig-
nificant regioselectivity can be achieved in favor of exposed SeM
residues and that minimally engineered proteins can be benzylated
to form useful constructs. Alternatively, conservative Met to Leu
mutations could be utilized to eliminate undesired reactivity as
shown for Met-specific protein conjugates (19, 42).
Simultaneous, Orthogonal Labeling of SeM and Cys. Drawing inspi-
ration from Palmer’s early report (35), we strove to exploit the
unique reactivity profiles of SeM and Cys in protein 7 to conjugate
two distinct tags (Fig. 8B). Treating GATE-16 7 (200 μM) with
both BrMePAA tag 8 (800 μM) and maleimide tag 10 (800 μM),
at pH 5 for 12 h, resulted in a conjugate that was fully labeled at
Cys7 and had a similar SeM-labeling distribution as observed
when labeling with tag 8 alone. When used in concert with
established Cys modification reagents, the SeM benzylation allows
for complex protein systems to be quickly and selectively modified
in one pot, using two distinct tags.
Conclusion. In summary, we present a detailed study of the SeM
benzylation reaction and demonstrate its utility for protein bio-
conjugation. The chemical orthogonality of the reaction toward
all proteogenic nucleophiles as well as common thiol-labeling
reagents is demonstrated. We have also outlined the stability
of the selenonium conjugate under physiological conditions and
suggested its lability to cytosolic glutathione could act as a re-
lease mechanism for the conjugate inside cells. Compatibility of
the approach with auxotrophically expressed proteins suggests
broad application. The SeM benzylation can also be used in
concert with traditional thiol-maleimide chemistry to yield dual
modified proteins. Importantly, the electronic optimization of
the benzyl bromide electrophile identified BrMePAA as a
readily introduced reactive linker that facilitates room temper-
ature selective SeM labeling at submillimolar concentration. We
anticipate that SeM benzylation using BrMePAA will be a
valuable addition to the bioconjugation toolbox.
Fig. 5. (A) Modification of SpA (PDB: 1BDD) protein 3 with tags varying pH
(0.15 mM 3; 0.2 mM tag 4, 5, or 6; 20 mM MES; 10 mM ascorbic acid). (B)
HPLC chromatogram of reaction of 3 and 5 (0.15 mM 3, 0.2 mM tag 6, 20 mM
MES buffer pH 5). Deconvolution was performed manually from centroid
collapsed peaks between m/z 600 and 1,250.
Fig. 6. (A) Tev-GATE-16 (PDB: 4CO7) 7 surface, SeM residues shown in blue,
Se highlighted in orange, and the Cys residue shown in green. (B) Labeling
conditions. (C) Mass spectrum of starting material and labeled product.
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Peptide and Protein Synthesis. Peptides were chain assembled by N-(9-
fluorenylmethoxycarbony)–solid phase peptide synthesis, deprotected, and
cleaved from the resin with trifluoroacetic acid/scavengers and purified by
HPLC (43). The polypeptide corresponding to the SpA domain was assembled
by native chemical ligation of two synthetic peptides and folded in PBS (SI
Appendix) (43).
Monitoring of Reaction Progress. The consumption of peptide 1 was moni-
tored by integration of ultraviolet (UV) absorbance ultrahigh-performance
liquid chromatography (UPLC) 1-μL aliquots, by autosampler, at 3- to
12-min intervals. For all spectra, UV absorbance at 277 nm was auto-
integrated against an internal standard (Boc-Tyr-OH). All mass spectra
were obtained by integration of the total ion current (TIC) over the entire
peak area.
Initial Rate Study. Substituted benzyl bromide (BrMePAA or p-CN BnBr) was
reacted with peptide 1 in 30% acetonitrile, 5% DMSO, 40 mM mercaptoe-
thylsulfonic acid (MES), 10 mM ascorbic acid at pH 6. Ascorbic acid was added
to selectively reduce any SeM selenoxide side products while not reducing
sulfoxides or disulfides (44). Reaction progress was monitored by UPLC-MS
and the initial rate was determined through linear regression.
Hammett Analysis. Peptide 1 (1 mM) was reacted with 2 equiv. substituted
benzyl bromide (X-BnBr) in a solution of 30% acetonitrile, 5% DMSO, 40 mM
MES buffer, 10 mM ascorbic acid, pH 6. Reaction progress was monitored by
UPLC-MS and rate constant was determined by fitting data to the second-
order integrated rate law. The log of the ratio of the initial rate of each p-X
BnBr to the initial rate of p-H BnBr was plotted against known p-Hammett
constants.
Conjugate Stability.
Serum mimic conditions. Purified benzyl-selenonium adducts of peptide 1were
dissolved in PBS, pH 7.4 with Boc-Tyr-OH as an internal standard and sam-
pled for 36 d.
Cytosol mimic conditions. Purified benzyl-selenonium adducts of peptide 1 were
dissolved in PBS, pH 7.4 with 7.5 mM GSH and Boc-Tyr-OH as an internal
standard. The mixture was monitored every 12 min for 3 h, by UPLC-MS.
Expressed Protein Labeling. Proteins 7 and 9were diluted into buffer containing
15 mM phosphate-citrate, 10 mM ascorbic acid at specified pH. The conjugation
was initiated by adding 8 (from a 20× or 50× stock in dimethylamine or
DMSO). The final organic solvent concentration was less than or equal to
5% vol/vol. The reactions were allowed to incubate at room temperature
for 12 h at which point they were analyzed by UPLC time-of-flight mass
spectrometry. Chromatographic separation was not achieved, so the
entire TIC peak was combined and deconvoluted by built-in Max Ent
1 software.
Data Availability.All study data are included in this article and/or SI Appendix.
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